Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan, a multi-specialty health care company focused on discovering developing and commercialising pharmaceuticals biologics, has reported revenues of $1.15bn for the first quarter ended March 31, 2010, compared to $1bn for the comparable period in 2009.
Subscribe to our email newsletter
Allergan has posted a net income of $169m for the first quarter of 2010, compared to $45m for the prior year period. Operating income was $250.3m, compared to $82.1 for the year ago period.
For the second quarter of 2010, the company expects total product net sales between $1,190m and $1,230m, and non-GAAP diluted earnings per share attributable to stockholders between $0.79 and $0.81, which includes the estimated impact of US healthcare reform legislation.
David Pyott, chairman of the board and CEO of Allergan, said: “During the first quarter, Allergan continued to actively expand its product portfolio and geographic reach through business development activities and the attainment of important regulatory approvals. In addition, we delivered strong operating results as we benefited from the increasing strength of our cash pay businesses.”